Physician profile
Stephanie Dalton
NPI 1043579766
$1,964.84
in general payments reported to CMS, 2019-2025
31 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $191 · 2021: $136 · 2022: $254 · 2023: $302 · 2024: $79.69 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $337.98 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Supernus Pharmaceuticals, INC. | $255.18 | 2019-2022 | |
| Abbvie INC. | $188.23 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Amneal Pharmaceuticals LLC | $178.18 | 2020-2025 | Crexont, Rytary |
| Jazz Pharmaceuticals INC. | $85.42 | 2023-2025 | |
| Ucb, INC. | $78.11 | 2019-2025 | Zilbrysq |
| Argenx US, INC. | $73.56 | 2025 | Vyvgart |
| Pfizer INC. | $73.49 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $60.88 | 2021-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $59.06 | 2019-2025 | |
| Genentech USA, INC. | $56.98 | 2019-2025 | Ocrevus Zunovo |
| Genzyme Corporation | $51.96 | 2019-2024 | |
| Grifols USA, LLC | $48.76 | 2025 | Gamunex-C |
| Lilly USA, LLC | $47.39 | 2019-2025 | Kisunla, Amyvid |
| Tg Therapeutics, INC. | $45.82 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $43.09 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.42 | 2023 | Hyqvia |
| Eisai INC. | $23.64 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.94 | 2023 | Nuedexta |
| Csl Behring | $22.62 | 2022 | |
| Banner Life Sciences, LLC | $20.81 | 2022 | |
| Ge Healthcare | $20.65 | 2019 | |
| Acorda Therapeutics, INC | $20.48 | 2019 | |
| Janssen Biotech, INC. | $17.66 | 2025 | |
| Corium, LLC | $17.20 | 2023 | Adlarity |
| Kyowa Kirin, INC. | $16.11 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.57 | 2021 | |
| Acadia Pharmaceuticals INC | $13.13 | 2023 | Nuplazid |
| Allergan, INC. | $12.18 | 2020 | |
| Amgen INC. | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.